Travere Therapeutics, Inc.
Clinical trials sponsored by Travere Therapeutics, Inc., explained in plain language.
-
New hope for transplant patients: drug targets protein spill in kidneys
Disease control Recruiting nowThis study tests a drug called sparsentan in 20 adults who have had a kidney transplant and still have protein in their urine due to IgA nephropathy or FSGS. The goal is to see if the drug can safely reduce protein levels over 36 weeks. Participants take one pill daily, and the s…
Phase: PHASE4 • Sponsor: Travere Therapeutics, Inc. • Aim: Disease control
Last updated May 17, 2026 10:45 UTC
-
New hope for kids with rare kidney diseases: sparsentan trial aims to cut protein leakage
Disease control Recruiting nowThis study tests an oral drug called sparsentan in 67 children with certain kidney diseases that cause protein in the urine. The goal is to see if the drug safely reduces protein leakage and helps control the disease over about two years. Participants take the drug once daily, an…
Phase: PHASE2 • Sponsor: Travere Therapeutics, Inc. • Aim: Disease control
Last updated May 17, 2026 10:42 UTC
-
New hope for rare metabolic disorder: phase 3 drug trial targets toxic amino acid buildup
Disease control Recruiting nowThis study tests an experimental drug called pegtibatinase in people with classical homocystinuria, a rare genetic disorder that causes dangerously high levels of homocysteine in the blood. About 70 participants aged 12 to 65 will receive either the drug or a placebo alongside th…
Phase: PHASE3 • Sponsor: Travere Therapeutics, Inc. • Aim: Disease control
Last updated May 14, 2026 12:04 UTC